A lncRNA Decoy Predicts Sensitivity to Cisplatin

Raquel Boque-Sastre; Sonia Guil

doi:10.1016/j.molmed.2020.01.015

A lncRNA Decoy Predicts Sensitivity to Cisplatin

Trends Mol Med. 2020 Apr;26(4):352-354. doi: 10.1016/j.molmed.2020.01.015. Epub 2020 Feb 18.

Authors

Raquel Boque-Sastre¹, Sonia Guil²

Affiliations

¹ Cardiff School of Biosciences, Cardiff University, Museum Avenue, Cardiff, CF10 3AX, UK.
² Josep Carreras Leukaemia Research Institute (IJC), 08916 Badalona, Barcelona, Catalonia, Spain. Electronic address: sguil@carrerasresearch.org.

PMID: 32277928
DOI: 10.1016/j.molmed.2020.01.015

Abstract

In a recent iScience paper by Fan et al., the long noncoding (lnc)RNA CISAL is shown to form a DNA-RNA triplex and to directly regulate BRCA1 transcription, thereby increasing cisplatin sensitivity and serving as a treatment efficacy biomarker. This opens promising avenues of research from both mechanistic and translational perspectives.

Keywords: BRCA1; GABPA; TSCC; chemoresistance; lncRNA CISAL; triplex.

Publication types

Comment